drugset / Trial / NCT00818064

Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis

NCT00818064

Phase 1 Completed 32 enrolled Novo Nordisk A/S
RandomizedSingle-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety and tolerability of single doses of Anti-IL-20 in healthy volunteers (HV) and patients with rheumatoid arthritis (RA).

Timeline

Start
2008-12
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FLETIKUMAB Monoclonal antibody Subcutaneous

Indications